Teva Pharmaceutical Industries Ltd. $TEVA Shares Sold by Ethic Inc.

Ethic Inc. reduced its stake in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 7.0% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 18,490 shares of the company’s stock after selling 1,399 shares during the quarter. Ethic Inc.’s holdings in Teva Pharmaceutical Industries were worth $310,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Bourgeon Capital Management LLC lifted its position in shares of Teva Pharmaceutical Industries by 100.7% in the second quarter. Bourgeon Capital Management LLC now owns 723,974 shares of the company’s stock valued at $12,134,000 after acquiring an additional 363,252 shares in the last quarter. Amundi lifted its position in shares of Teva Pharmaceutical Industries by 18.5% in the first quarter. Amundi now owns 678,758 shares of the company’s stock valued at $10,080,000 after acquiring an additional 105,846 shares in the last quarter. IFM Investors Pty Ltd lifted its position in shares of Teva Pharmaceutical Industries by 9.4% in the second quarter. IFM Investors Pty Ltd now owns 226,534 shares of the company’s stock valued at $3,797,000 after acquiring an additional 19,447 shares in the last quarter. Jump Financial LLC lifted its position in shares of Teva Pharmaceutical Industries by 172.1% in the first quarter. Jump Financial LLC now owns 1,325,526 shares of the company’s stock valued at $20,373,000 after acquiring an additional 838,423 shares in the last quarter. Finally, Sumitomo Mitsui Trust Group Inc. lifted its position in shares of Teva Pharmaceutical Industries by 5.7% in the first quarter. Sumitomo Mitsui Trust Group Inc. now owns 2,504,007 shares of the company’s stock valued at $38,487,000 after acquiring an additional 134,705 shares in the last quarter. 54.05% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several brokerages have recently issued reports on TEVA. Weiss Ratings restated a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a research report on Wednesday, October 8th. Wall Street Zen upgraded Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research report on Saturday, October 11th. JPMorgan Chase & Co. increased their target price on Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the stock an “overweight” rating in a research report on Friday, October 3rd. Finally, UBS Group increased their target price on Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the stock a “buy” rating in a research report on Wednesday, September 24th. Two investment analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $25.57.

Teva Pharmaceutical Industries Stock Performance

Shares of NYSE:TEVA opened at $20.20 on Thursday. The firm has a market capitalization of $23.16 billion, a PE ratio of -126.22, a P/E/G ratio of 1.09 and a beta of 0.71. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.06 and a quick ratio of 0.77. The business has a 50-day moving average of $19.21 and a two-hundred day moving average of $17.45. Teva Pharmaceutical Industries Ltd. has a 12 month low of $12.47 and a 12 month high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings results on Wednesday, July 30th. The company reported $0.66 EPS for the quarter, topping the consensus estimate of $0.64 by $0.02. The company had revenue of $4.18 billion during the quarter, compared to analyst estimates of $4.34 billion. Teva Pharmaceutical Industries had a positive return on equity of 46.10% and a negative net margin of 0.95%.The firm’s revenue was up .3% on a year-over-year basis. During the same period in the prior year, the firm posted $0.61 earnings per share. As a group, research analysts forecast that Teva Pharmaceutical Industries Ltd. will post 2.5 earnings per share for the current year.

Insider Activity

In other Teva Pharmaceutical Industries news, insider Eric A. Hughes sold 52,742 shares of the company’s stock in a transaction dated Friday, August 1st. The stock was sold at an average price of $15.16, for a total transaction of $799,568.72. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Placid Jover sold 6,053 shares of the company’s stock in a transaction dated Friday, August 1st. The stock was sold at an average price of $15.16, for a total value of $91,763.48. Following the sale, the insider owned 6,774 shares of the company’s stock, valued at $102,693.84. This represents a 47.19% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Corporate insiders own 0.49% of the company’s stock.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.